• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CureVac stock soars after $213.3M IPO

August 17, 2020 By Sean Whooley

Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday.

According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are trading up 30.2% at $72.77.

The company announced the IPO last Monday, setting the sale range between $14 and $16 per share. In the announcement, CureVac said it intends to use the net proceeds collected from its IPO and a concurrent private placement (the company closed its latest private financing round at $640 million) to fund its mRNA vaccine program against SARS-CoV-2 through the completion of Phase 3.

Additionally, the company intends to fund the expansion of its short-term manufacturing capabilities and to advance a number of its programs through their Phase 2 clinical trials, including programs in oncology and rabies.

CureVac, which is developing a COVID-19 vaccine with backing from the Bill and Melinda Gates Foundation, reportedly gained 249% on its first day of trading last week, and continues to rise after CEO Franz-Werner Haas said in an interview with Boerse Online recently that he was hopeful the company’s vaccine candidate will receive regulatory clearance early next year.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: coronavirus, COVID-19, CureVac

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS